[go: up one dir, main page]

PE20081351A1 - Derivados de quinazolina como agentes anticancerigenos - Google Patents

Derivados de quinazolina como agentes anticancerigenos

Info

Publication number
PE20081351A1
PE20081351A1 PE2007001740A PE2007001740A PE20081351A1 PE 20081351 A1 PE20081351 A1 PE 20081351A1 PE 2007001740 A PE2007001740 A PE 2007001740A PE 2007001740 A PE2007001740 A PE 2007001740A PE 20081351 A1 PE20081351 A1 PE 20081351A1
Authority
PE
Peru
Prior art keywords
cancer agents
ethyl
amino
quinazoline derivatives
quinazolin
Prior art date
Application number
PE2007001740A
Other languages
English (en)
Inventor
Brian Aquila
Donald James Cook
Stephen Lee
Paul Lyne
Melissa Vasbinder
Haixia Wang
Craig Johnstone
David Alan Rudge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39386079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081351(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20081351A1 publication Critical patent/PE20081351A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE QUINAZOLINA DE FORMULA (I), DONDE R1 ES HALOGENO, NITRO, CIANO, OH, TRIFLUOROMETOXI, ENTRE OTROS; n ES UN ENTERO DE 0 A 4; R2 ES HALOGENO, AMINO, CARBAMOILO, CARBOXI, ENTRE OTROS; m ES UN ENTERO DE 0 A 4. SON COMPUESTOS PREFERIDOS: N-[(1R)-1-(4-{[6-(4-METILPIRIDIN-3-IL)QUINAZOLIN-2-IL]AMINO}FENIL)ETIL]ACETAMIDA, 4-(6-BROMOQUINAZOLIN-2-ILAMINO)-N-(2-(DIMETILAMINO)ETIL)BENCENSULFONAMIDA, 3-METOXI-N-[(1R)-1-(4-{[6-(4-METILPIRIDIN-3-IL)QUINAZOLIN-2-IL]AMINO}FENIL)ETIL]PROPANAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINASA B-RAF Y SON UTILES COMO AGENTES ANTICANCERIGENOS
PE2007001740A 2006-12-08 2007-12-07 Derivados de quinazolina como agentes anticancerigenos PE20081351A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86924106P 2006-12-08 2006-12-08
US98573207P 2007-11-06 2007-11-06

Publications (1)

Publication Number Publication Date
PE20081351A1 true PE20081351A1 (es) 2008-11-26

Family

ID=39386079

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001740A PE20081351A1 (es) 2006-12-08 2007-12-07 Derivados de quinazolina como agentes anticancerigenos

Country Status (5)

Country Link
AR (1) AR064208A1 (es)
CL (1) CL2007003557A1 (es)
PE (1) PE20081351A1 (es)
TW (1) TW200829566A (es)
WO (1) WO2008068507A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
CN101652352A (zh) * 2006-12-22 2010-02-17 诺瓦提斯公司 用于抑制pdk1的喹唑啉类
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CN101663299A (zh) 2007-04-23 2010-03-03 詹森药业有限公司 作为快速解离性多巴胺2受体拮抗剂的噻(二)唑类化合物
KR20100016620A (ko) 2007-04-23 2010-02-12 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 4-알콕시피리다진 유도체
ES2622161T3 (es) 2008-07-31 2017-07-05 Janssen Pharmaceutica, N.V. Piridinas sustituidas con piperazin-1-il-trifluorometilo como antagonistas del receptor de la dopamina 2 de disociación rápida
NZ594508A (en) 2009-02-13 2013-12-20 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
EP3318027B1 (en) 2015-06-30 2019-10-30 British Telecommunications public limited company Quality of service management in a network
EP4491740A3 (en) 2016-09-02 2025-02-26 New England Biolabs, Inc. Analysis of chromatin using a nicking enzyme
CN111170986A (zh) * 2018-11-13 2020-05-19 北京睿熙生物科技有限公司 布鲁顿酪氨酸激酶的抑制剂
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023138412A1 (en) * 2022-01-20 2023-07-27 Insilico Medicine Ip Limited Fused pyrimidin-2-amine compounds as cdk20 inhibitors
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025092989A1 (zh) * 2023-11-03 2025-05-08 泰州红云制药有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004281154A1 (en) * 2003-10-16 2005-04-28 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use

Also Published As

Publication number Publication date
AR064208A1 (es) 2009-03-18
WO2008068507A2 (en) 2008-06-12
WO2008068507A3 (en) 2008-07-31
TW200829566A (en) 2008-07-16
CL2007003557A1 (es) 2008-08-01

Similar Documents

Publication Publication Date Title
PE20081351A1 (es) Derivados de quinazolina como agentes anticancerigenos
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
PE20090434A1 (es) Derivados de sulfonil amida como inhibidores de quinasas
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
PE20090837A1 (es) Nuevos compuestos quimicos
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
PE20070593A1 (es) Compuestos pirrolopirimidina como inhibidores de syk
IL177280A (en) Monohydrate crystal of 2-aminothiazole-5-aromatic carboxamide, process for its preparation, its pharmaceutical composition and its use in the preparation of medicine
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
PE20040647A1 (es) Inhibidores de cinasas de tirosina
PE20081256A1 (es) Triazalopiridacina como modulador de la actividad proteina cinasa
SE0402735D0 (sv) Novel compounds
EA200870461A1 (ru) Производные лактама циклогексилимидазола в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
PE20121314A1 (es) Derivados de 4-aminociclohexano sustituido
BRPI0514750A (pt) derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
EA200701705A1 (ru) Антагонисты рецепторы глюкагона, получение и терапевтическое применение
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
DK1735278T3 (da) Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20070113A1 (es) Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb
PE20110584A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIMIDINA COMO INHIBIDORES DE MET, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU PROCEDIMIENTO DE PREPARACION

Legal Events

Date Code Title Description
FA Abandonment or withdrawal